

APPLICATION FOR MATERIAL LICENSE

INSTRUCTIONS: SEE THE APPROPRIATE LICENSE APPLICATION GUIDE FOR DETAILED INSTRUCTIONS FOR COMPLETING APPLICATION. SEND TWO COPIES OF THE ENTIRE COMPLETED APPLICATION TO THE NRC OFFICE SPECIFIED BELOW.

APPLICATIONS FOR DISTRIBUTION OF EXEMPT PRODUCTS FILE APPLICATIONS WITH:

U.S. NUCLEAR REGULATORY COMMISSION
DIVISION OF INDUSTRIAL AND MEDICAL NUCLEAR SAFETY, NMSS
WASHINGTON, DC 20555

ALL OTHER PERSONS FILE APPLICATIONS AS FOLLOWS, IF YOU ARE LOCATED IN:

CONNECTICUT, DELAWARE, DISTRICT OF COLUMBIA, MAINE, MARYLAND, MASSACHUSETTS, NEW HAMPSHIRE, NEW JERSEY, NEW YORK, PENNSYLVANIA, RHODE ISLAND, OR VERMONT, SEND APPLICATIONS TO:

U.S. NUCLEAR REGULATORY COMMISSION, REGION I
NUCLEAR MATERIALS SAFETY SECTION B
475 ALLENDALE ROAD
KING OF PRUSSIA, PA 19406

ALABAMA, FLORIDA, GEORGIA, KENTUCKY, MISSISSIPPI, NORTH CAROLINA, PUERTO RICO, SOUTH CAROLINA, TENNESSEE, VIRGINIA, VIRGIN ISLANDS, OR WEST VIRGINIA, SEND APPLICATIONS TO:

U.S. NUCLEAR REGULATORY COMMISSION, REGION II
NUCLEAR MATERIALS SAFETY SECTION
101 MARIETTA STREET, SUITE 2900
ATLANTA, GA 30333

IF YOU ARE LOCATED IN:

ILLINOIS, INDIANA, IOWA, MICHIGAN, MINNESOTA, MISSOURI, OHIO, OR WISCONSIN, SEND APPLICATIONS TO:

U.S. NUCLEAR REGULATORY COMMISSION, REGION III
MATERIALS LICENSING SECTION
799 ROOSEVELT ROAD
GLEN ELLYN, IL 60137

ARKANSAS, COLORADO, IDAHO, KANSAS, LOUISIANA, MONTANA, NEBRASKA, NEW MEXICO, NORTH DAKOTA, OKLAHOMA, SOUTH DAKOTA, TEXAS, UTAH, OR WYOMING, SEND APPLICATIONS TO:

U.S. NUCLEAR REGULATORY COMMISSION, REGION IV
MATERIAL RADIATION PROTECTION SECTION
811 RYAN PLAZA DRIVE, SUITE 1000
ARLINGTON, TX 76011

ALASKA, ARIZONA, CALIFORNIA, HAWAII, NEVADA, OREGON, WASHINGTON, AND U.S. TERRITORIES AND POSSESSIONS IN THE PACIFIC, SEND APPLICATIONS TO:

U.S. NUCLEAR REGULATORY COMMISSION, REGION V
NUCLEAR MATERIALS SAFETY SECTION
1460 MARIA LANE, SUITE 210
WALNUT CREEK, CA 94596

29-30272-01
L&L 30272
030-
02200

PERSONS LOCATED IN AGREEMENT STATES SEND APPLICATIONS TO THE U.S. NUCLEAR REGULATORY COMMISSION ONLY IF THEY WISH TO POSSESS AND USE LICENSED MATERIAL IN STATES SUBJECT TO U.S. NUCLEAR REGULATORY COMMISSION JURISDICTION.

1. THIS IS AN APPLICATION FOR (Check appropriate item)

- A. NEW LICENSE
- B. AMENDMENT TO LICENSE NUMBER _____
- C. RENEWAL OF LICENSE NUMBER _____

2. NAME AND MAILING ADDRESS OF APPLICANT (Include Zip Code)

Magnetic Resonance of New Jersey
410 Centre Street
Nutley, New Jersey 07110

3. ADDRESS(ES) WHERE LICENSED MATERIAL WILL BE USED OR POSSESSED.

410 Centre Street
Nutley, New Jersey

4. NAME OF PERSON TO BE CONTACTED ABOUT THIS APPLICATION

John M. Gochoco, M.S.

TELEPHONE NUMBER

201-533-5590

SUBMIT ITEMS 5 THROUGH 11 ON 8 1/2" PAPER. THE TYPE AND SCOPE OF INFORMATION TO BE PROVIDED IS DESCRIBED IN THE LICENSE APPLICATION GUIDE

- 5. RADIOACTIVE MATERIAL
a. Element and mass number, b. chemical and/or physical form, and c. maximum amount which will be possessed at any one time.
- 7. INDIVIDUAL(S) RESPONSIBLE FOR RADIATION SAFETY PROGRAM AND THEIR TRAINING AND EXPERIENCE.
- 9. FACILITIES AND EQUIPMENT.
- 11. WASTE MANAGEMENT.

- 6. PURPOSE(S) FOR WHICH LICENSED MATERIAL WILL BE USED.
- 8. TRAINING FOR INDIVIDUALS WORKING IN OR FREQUENTING RESTRICTED AREAS.
- 10. RADIATION SAFETY PROGRAM.

13. CERTIFICATION. (Must be completed by applicant) THE APPLICANT UNDERSTANDS THAT ALL STATEMENTS AND REPRESENTATIONS MADE IN THIS APPLICATION ARE BINDING UPON THE APPLICANT.

THE APPLICANT AND ANY OFFICIAL EXECUTING THIS CERTIFICATION ON BEHALF OF THE APPLICANT, NAMED IN ITEM 2, CERTIFY THAT THIS APPLICATION IS PREPARED IN CONFORMITY WITH TITLE 10, CODE OF FEDERAL REGULATIONS, PARTS 30, 32, 33, 34, 35, AND 40 AND THAT ALL INFORMATION CONTAINED HEREIN, IS TRUE AND CORRECT TO THE BEST OF THEIR KNOWLEDGE AND BELIEF.

WARNING: 18 U.S.C. SECTION 1001 ACT OF JUNE 25, 1948, 62 STAT. 749 MAKES IT A CRIMINAL OFFENSE TO MAKE A WILLFULLY FALSE STATEMENT OR REPRESENTATION TO ANY DEPARTMENT OR AGENCY OF THE UNITED STATES AS TO ANY MATTER WITHIN ITS JURISDICTION.

SIGNATURE—CERTIFYING OFFICER	TYPED/PRINTED NAME	TITLE	DATE
	Robert F. Traflet, M.D.	Owner/Physician	1/5/96

FOR NRC USE ONLY

TYPE OF FEE	FEE LOG	FEE CATEGORY	COMMENTS
AMOUNT RECEIVED	CHECK NUMBER		

APPROVED BY	DATE
-------------	------

Magnetic Resonance of New Jersey
410 Centre Street
Nutley, New Jersey 07110
(201) 661-2000

Supplementary Information

Items #5 and 6 - Materials and Purpose

<u>By Product Material</u>	<u>Amount</u>	<u>Purpose</u>
5a. Material in 35.100	As needed	Medical use
5b. Material in 35.200	As needed	Medical use

Item #7 - Radiation Safety Officer and Authorized User

Please list **Patrick J. Conte, M.D.** as the Radiation Safety Officer and Authorized User (35.100 and 35.200). Enclosed is Dr. Conte's C.V. for your review. Please note that Dr. Conte is currently approved as the Radiation Safety Officer and Authorized User on an NRC license.

Enclosed for your review regarding Dr. Conte:

- Current C.V.
- Certificate, American Board of Diagnostic Radiology
- Certificate, American Board of Nuclear Medicine
- USNRC License #29-06759-01 (St. Michaels Medical Center, Newark, NJ)
- NJSL License #70004-02 (St. Michaels Medical Center, Newark, NJ)

Item #8 - Employee Training

We will follow the model training program as published in Appendix A to Regulatory Guide 10.8, Revision 2.

Item #9 - Facilities and Equipment

- 9a) A facilities diagram is attached (ATT 9.1) .
- 9b) A list of equipment is attached (ATT 9.2) .
- 9c) Survey meters will be calibrated by a facility licensed by the NRC.

Survey meters will be checked for proper operation with a dedicated check source each day of use per 10CFR 35.51(c) .

A back-up survey instrument will be available if the meter is off-site or inoperable.

9d) We will follow the model procedures for calibrating our dose calibrator as published in Appendix C to Regulatory Guide 10.8, Revision 2 . Linearity will be established down to 30 microcuries.

9e) We will follow the model procedure for personnel monitoring as published in Appendix D to Regulatory Guide 10.8, Revision 2 .

Nuclear medicine technologist dosimeters will be exchanged monthly by an NVLAP accredited service (e.g. Landauer, Inc. or Siemens, Inc.).

Item #10 - Radiation Safety Program

10a) We will establish and implement the model ALARA program that was published in Appendix G to Regulatory Guide 10.8, Revision 2, with the exception that since this is a private office, the organization will not include a radiation safety committee or any functions delegated to a radiation safety committee.

10b) We will establish and implement the model procedure for leak-testing sealed sources that was published in Appendix H to Regulatory Guide 10.8, Revision 2

10c) We will follow the model rules for safe use of radiopharmaceuticals as published in Appendix I to Regulatory Guide 10.8, Revision 2 .

10d) We will follow the model spill procedures as published in Appendix J to Regulatory Guide 10.8, Revision 2 .

10e) We will establish and implement the model guidance for ordering and receiving radioactive material that was published in Appendix K to Regulatory Guide 10.8, Revision 2 .

10f) We will follow the model procedure for opening packages as published in Appendix L to the Regulatory Guide 10.8, Revision 2 .

10g) We will follow the model procedure for records of unit doses as published in Appendix M.1 to Regulatory Guide 10.8, Revision 2 . Mo/Tc generators will not be used at this facility.

10h) We will follow the model procedure for performing area surveys as published in Appendix N to Regulatory Guide 10.8, Revision 2 .

We will set our action levels for surface contamination by radiopharmaceuticals according to Table N-1 in Regulatory Guide 10.8, Revision 2 .

The action level for ambient exposure will be 0.5 mR/hr for unrestricted areas and 5 mR/hr for restricted areas.

Item #11 - Waste Management

Those materials not returned to the central radiopharmacy shall be disposed of via decay-in-storage (DIS) . The model procedure for DIS, as given in Appendix R to Regulatory Guide 10.8, Revision 2, shall be followed.

ATT. 9.2

LIST OF EQUIPMENT


HOT LAB :

1. (1) Dose Calibrator
2. (1) Detection Survey Meter with pancake probe and dedicated check source
3. (2) Pro Tec II Syringe Shields #007-800 3cc and #007-900 5cc
4. (1) Standard table shield double lead glass #042-316
5. (1) Lead Lined Waste Container (20 qts) #039-100
6. (1) Ludlum Nal Well Wipe Test Counter #075-578
7. (1) Lead Shielded Syringe Holder #009-220
8. (2) Lead Lined Syringe Storage Containers #050-200

IMAGING ROOM :

1. (1) Technicare 438HR S/N 336 MCS 560 Gamma Camera and Computer

MAGNETIC RESONANCE OF NEW JERSEY
NUCLEAR MEDICINE
410 CENTRE STREET
NUTLEY, NEW JERSEY 07450
(201) 661-2000



THE AMERICAN BOARD OF NUCLEAR MEDICINE

INCORPORATED 1971

A CONJOINT BOARD ORGANIZED WITH THE SPONSORSHIP OF THE AMERICAN BOARD OF INTERNAL MEDICINE,
AMERICAN BOARD OF PATHOLOGY, AMERICAN BOARD OF RADIOLOGY AND THE SOCIETY OF NUCLEAR MEDICINE
HEREBY CERTIFIES THAT

Patrick John Conte, Jr., M.D.


HAS MET THE REQUIREMENTS OF THIS BOARD AND IS
CERTIFIED AS QUALIFIED TO PRACTICE AS A SPECIALIST IN
ALL ASPECTS OF CLINICAL AND LABORATORY

NUCLEAR MEDICINE

INCLUDING BUT NOT LIMITED TO RADIOBIOASSAY, NUCLEAR IMAGING,
IN VIVO MEASUREMENTS AND THERAPY WITH UNSEALED RADIONUCLIDES


Merrill A. Bender
CHAIRMAN




Joseph F. Ross, M.D.
SECRETARY

NUMBER 01419

DATE MAY 5, 1972

The American Board of Radiology

Organized through the cooperation of the
American College of Radiology, the American Roentgen Ray Society,
the American Radium Society, the Radiological Society of North America
and the Section on Radiology of the American Medical Association

Nowby certifies that

Patrick John Conte, Jr., M.D.

Has pursued an accepted course of graduate study and clinical work, has met certain standards
and qualifications and has passed the examination conducted under the authority of

The American Board of Radiology

Thereby demonstrating to the satisfaction of the Board that he is qualified to practice the specialty of
Diagnostic Radiology

And further, the American Board of Radiology, acting in conjunction and cooperation with

The American Board of Nuclear Medicine

Conjoint board formed with the sponsorship of the American Board of Internal Medicine, the American
Board of Pathology, The American Board of Radiology and the Society of Nuclear Medicine

On this the twenty-ninth day of June, 1974

acknowledges Special Competence in
Nuclear Radiology



Robert N. Cooley
President

A. Allen Good
Secretary

Joseph F. Ross
President

John V. Schaefer
Secretary



CURRICULUM VITAE

PATRICK J. CONTE, M.D.

- EDUCATION: Seton Hall University
South Orange, NJ
Sept. 1958-June 1961
- Stritch School of Medicine of Loyola University
Chicago, Illinois
M.D. Degree, June 12, 1966
- INTERNSHIP: Straight Medical Internship
Upstate Medical Center, SUNY
Syracuse, NY
1966-1967
- RESIDENCY: General Radiology Residency
Upstate Medical Center, SUNY
Syracuse, NY
1967-1970
- FELLOWSHIP: Nuclear Medicine
Upstate Medical Center, SUNY
Syracuse, NY
1970-1971

HOSPITAL APPOINTMENTS:

Medical Director, Nuclear Medicine and Visceral
Ultrasonography, Department of Medicine,
Senior Attending, Department of Medicine
Senior Attending, Department of Radiology
Saint Michael's Medical Center, 268 Martin Luther King, Jr.
Blvd., Newark, NJ. 1993-present.

Consultant and Clinical Investigator, Nuclear Medicine Physician
Center for Molecular Medicine and Immunology,
One Bruce Street, Newark, NJ
1992-present

Clinical Assistant Professor of Radiology
University of Medicine and Dentistry of New Jersey-New Jersey
Medical School,
185 South Orange Avenue, University Heights,
Newark, NJ 1983-1994

PATRICK J. CONTE, M.D.

Director of Nuclear Medicine Section and Senior Attending,
Department of Radiology,
Saint Barnabas Medical Center, Old Short Hills Road,
Livingston, NJ 07039
1972 - 1988

Consultant Staff, Department of Radiology,
Saint Vincent's Hospital and Medical Center of New York,
153 West 11th Street, NY 10011
1977 - 1989

Assistant Clinical Professor, Department of Radiology,
Cornell University and Medical Center/ The New York Hospital
1300 York Avenue, NY 10021
1982 - 1988

TEACHING APPOINTMENTS:

Associate Professor, Department of Internal Medicine
Seton Hall University, School of Graduate Medical Education,
South Orange Avenue, NJ
1991 - present

Program Director, Nuclear Radiology Residency Program,
Department of Radiology, Saint Barnabas Medical Center,
Livingston, NJ
1979 - 1988

Clinical Instructor, Diagnostic Radiology Residency Program,
Department of Radiology, Saint Barnabas Medical Center,
Livingston, NJ 07039
1972 - 1988

Medical Director, Program of Nuclear Medicine Technology,
Radiology Department, Saint Barnabas Medical Center,
Livingston, NJ 07039
1975 - 1988

PATRICK J. CONTE, M.D.

Adjunct Professor, Baccalaureate Degree Program in Nuclear
Medicine Technology, Seton Hall University, South Orange, NJ
1982 - 1989

Clinical Instructor in Radiology, Nuclear Medicine and
Ultrasonography, Comprehensive Medical Review Course,
Department of Graduate Medical Education,
Saint Barnabas Medical Center, Livingston, NJ 07039
1976 - 1989

Clinical Instructor, Radiation Therapy Residency Program,
Department of Radiation Therapy, Saint Barnabas Medical Center,
Livingston, NJ 07039
1978 - 1988

Clinical Radiology Instructor, Department of Radiology,
Upstate Medical Center SUNY, Syracuse, NY
1970 - 1971

CERTIFICATIONS:

National Board of Medical Examiners, 1967
American Board of General Radiology, December 10, 1971
American Board of Nuclear Medicine, May 5, 1972
American Board of Nuclear Radiology, June 29, 1974

LICENSURE:

New York, August 3, 1967, License No. 099510
New Jersey, December 13, 1972, License No. 026569

PATRICK J. CONTE, M.D.

COMMITTEE APPOINTMENTS:

Investigational Review Board, Center for Molecular Medicine and Immunology, One Bruce Street, Newark, NJ

Radiation Safety Committee, Center for Molecular Medicine and Immunology, One Bruce Street, Newark, NJ

Radiation Safety Committee, Saint Michael's Medical Center, MLK, Jr., Blvd. Newark, NJ

Cancer Care Committee, Saint Michael's Medical Center, MLK Jr., Blvd., Newark, NJ

Co-Chairman, Radiation Protection Committee, Saint Barnabas Medical Center, Livingston, NJ
1980 - 1988

President, Advisory Board, Program of Nuclear Medicine Technology, Saint Barnabas Medical Center, Livingston, NJ
1980 - 1988

Tumor Board, Saint Barnabas Medical Center, Livingston, NJ
1978 - 1982

Medical Board, Saint Barnabas Medical Center, NJ
1982 - 1988

Tissue Review Committee, Saint Barnabas Medical Center
1980 - 1981

Society of Nuclear Medicine, Greater New York Chapter,
Finance Committee, 1982 - 1983
Bylaws Committee, 1983 - 1985

New Jersey Medical Society, Radiology Section,
Committee Chairman for 1982 Annual Meeting

President, Board of Health, Borough of Roseland
1980 - present

PATRICK J. CONTE, M.D.

MEDICAL SOCIETY MEMBERSHIPS:

American Medical Association
Society of Nuclear Medicine
Radiologic Society of North America
New Jersey Medical Society, Radiology Section
Essex County Medical Society
New Jersey Institute of Ultrasound in Medicine
Medical Advisory Board, Lupus Erythematosus Foundation
of New Jersey

PUBLICATIONS:

Radiology Consultant and Editor, Textbook,
Clinicians' Guide to Medical Imaging: Sturman, MF
Publisher, Williams and Wilkins, to be published in 1993

Update on Gallium-67 Concentration in Human Breast Milk:
Journal of Nuclear Medicine Technology, December 1983

Aortic Aneurysm Causing Multiple Liver Scan Defects:
American Journal of Roentgenology: March 1977

Demonstration of Meckel's Diverticulum With and Without
Perchlorate Premedication: Journal of Clinical Nuclear Medicine,
August 1976

Diagnosis of Bleeding Meckel's Diverticulum Using
Radiopertchnetate: American Journal of Gastroenterology,
March 1977

Radiologic Detection of Clinically Occult Cardiac Failure
Following Myocardial Infarction: British Journal of Radiology,
April 1971

Embryonal Rhabdomyosarcoma of the Middle Ear with Long Term
Survival: New England Journal of Medicine, January 1971

Viral Pneumonia: Roentgen-Pathologic Correlation:
Radiology, May 1970

PATRICK J. CONTE, M.D.

Calcified Mediastinal Bronchogenic Cysts: Radiology,
November 1969

What is Nuclear Medicine Technology? Audiovisual Program for
the Society of Nuclear Medicine, Technology Section, 1982

PICKER FOUNDATION PILOT GRANT:

Thyroid Scanning with Selenium-75 Selenomethionè and Gallium-
67 for the Detection of Thyroid Malignancy: 1971-1972

SCIENTIFIC EXHIBITS:

A Correlative Study of the Stability of Tc-99m Diphosphonate:
Society of Nuclear Medicine Annual Meeting, Chicago, ILL
June 1977

Detection of Focal Inflammatory Disease Using Gallium-67 Citrate:
Society of Nuclear Medicine Annual Meeting, Dallas, TX;
June 1976

Non-Malignant Causes of Positive Bone Scans Using Fluorine-18:
Nuclear Medicine Society Annual Meeting, Los Angeles, CA;
Silver Medal Award, June 1971

PRESENTATION OF SCIENTIFIC PAPERS:

Radiologic Detection of Clinically Occult Cardiac Failure
Following Myocardial Infarction:
Radiologic Society of North America, Chicago, IL
December 1968

Viral Pneumonia: Roentgen-Pathologic Correlation:
Radiologic Society of North America, Chicago, IL
December 1969

Aerosol Lung Imaging: Annual Meeting of The Society of Nuclear
Medicine, Midatlantic Section, Fredricksburg, VA April 1984

PATRICK J. CONTE, M.D.

VISITING PROFESSOR:

Quantitative Thallium Imaging: Visiting Professor,
Academy of Medicine of New Jersey, Saint Barnabas Medical Center,
Livingston, NJ June 1983

Dipyridamole Thallium Myocardial Imaging: Visiting Professor,
Radiology Grand Rounds, University Hospital, University of
Medicine and Dentistry of New Jersey, April 1986

Aerosol Lung Imaging: Visiting Professor,
Radiology Grand Rounds, University Hospital, UMDNJ,
April 1987

Hammoudeh, Haft, Conte. (1994) Correlation of Left Ventricular Wall Motion Abnormalities and Q Waves with Tc 99m-Sestamibi SPECT Perfusion Imaging. Abstract: Clinical Research; Vol. 42, No. 2, p. 196 A.

Hammoudeh, Haft, Conte. (1994) Poor Correlation of Pathological Q Waves with Sestamibi SPECT Myocardial Perfusion Abnormalities. Abstract: Clinical Research; Vol. 42, No. 2, p. 196 A.

Goldenberg, Sharkey, Udem, Vagg, Levine, Conte, Swayne, Hansen. (1994) Pneumocystis Carinii Pneumonia in AIDS Patients: A Method of Diagnosis By Radioimmunodetection (Immunoscintigraphy). J. Nucl. Med; Vol. 35, No. 5;1-10.

Goldenberg, Sharkey, Udem, Vagg, Levine, Conte, Swayne, Hansen. (1994) Immunoscintigraphy of Pneumocystis Carinii Pneumonia in AIDS Patients. J. Nucl. Med.; Vol. 35, No. 6;1028-1033.

Sharkey, Gold, Markowitz, Swayne, Conte, Goldenberg (1994) Initial Clinical Investigations of PAMAY, A New Murine Monoclonal Antibody Against Pancreatic Cancer. Abstract: Clin. Invest., Vol. 35; p. 219.

Sharkey, Dion, Swayne, Conte, Markowitz, Goldenberg. (1994) Radioimmunodetection of Epithelial Cancers with an Anti-MUC1 Murine Monoclonal Antibody. Abstract: Clin. Invest., Vol. 35; p. 219.

MATERIALS LICENSE

Amendment No. 42

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-436), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 39, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee

1. St. Michael's Medical Center
Division of Cathedral Health
Services, Inc.
2. 268 Dr. Martin Luther King Boulevard
Newark, New Jersey 07102

In accordance with the letter dated
May 25, 1994,
3. License number 29-06759-01 is amended in
its entirety to read as follows:

4. Expiration date April 30, 1996

5. Docket or
Reference No. 030-02490

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200 (except gas)	B. As needed
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300	C. As needed
D. Any byproduct material identified in 10 CFR 31.11	D. Prepackaged Kits	D. As needed
E. Americium 241	E. Sealed source (Amersham Model No. AMC-24)	E. 30 millicuries
F. Iodine 131	F. 6-Iodomethylnor-cholesterol	F. As needed
G. Iodine 131	G. Meta-Iodobenzylguanidine Sulfate	G. As needed

9. Authorized use

- A. Any uptake, dilution and excretion procedure approved in 10 CFR 35.100.
- Any imaging and localization procedure approved in 10 CFR 35.200.
- Any radiopharmaceutical therapy procedure approved in 10 CFR 35.300.
- In vitro studies.
- Use as an anatomical marker.
- Adrenal imaging in accordance with FDA IND 11,898.
- Adrenal medullary imaging in accordance with FDA IND 25,128.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

29-06759-01

Docket or Reference number

030-02490

Amendment No. 42

(Continued)

CONDITIONS

15. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material at a single location to quantities below the limits specified in 10 CFR 30.72 which require consideration of the need for an emergency plan for responding to a release of licensed material.
16. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR 71, "Packaging and Transportation of Radioactive Material."
17. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
 - A. Application dated May 4, 1990
 - B. Letter dated January 13, 1991

OFFICIAL RECORD COPY ML 10

122769